A Phase 3 interventional study of DOR/ISL and BIC/FTC/TAF in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 95 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL [also known as MK-8591A]) in treatment-naïve participants living with human immunodeficiency virus type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.
Double-blind treatment with the assigned intervention occurs from Day 1 to Week 96, followed by an open-label portion up to Week 144. Participants who benefit from treatment in the opinion of the Investigator may continue their assigned intervention up to Week 168 (or until they have the option to enroll in a DOR/ISL 100 mg/0.25 mg study, whichever is sooner).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment-naïve participants living with human immunodeficiency virus-1 (HIV-1) that had not received ≤10 days of prior antiretroviral therapy received blinded fixed dose combination (FDC) Doravirine/Islatravir (DOR/ISL) (100 mg doravirine \[DOR\]/0.75 mg islatravir \[ISL\]) and placebo to Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/FTC/TAF) once daily (QD) from Day 1 to Week 96, and open-label DOR/ISL up to Week 144. At Week 144, participants who consent to enter the optional open-label study extension continued to receive open-label QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.
Drug: DOR/ISL · Drug: Placebo to BIC/FTC/TAF
Treatment-naïve participants living with HIV-1 that had not received ≤10 days of prior antiretroviral therapy received blinded BIC/FTC/TAF (50 mg bictegravir \[BIC\], 200 mg emtricitabine \[FTC\], 25 mg tenofovir alafenamide \[TAF\]) and placebo to FDC DOR/ISL QD from Day 1 to Week 96, and open-label BIC/FTC/TAF up to Week 144. At Week 144, participants who consent to enter the optional open-label study extension continued to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.
Drug: BIC/FTC/TAF · Drug: Placebo to DOR/ISL
Drug pages: Doravirine · Islatravir
100 mg DOR/0.75 mg ISL FDC single tablet taken once daily by mouth.
Also known as: MK-8591A, Doravirine/islatravir
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
BIC/FTC/TAF 50/200/25 mg FDC single tablet taken once daily by mouth.
Also known as: Bictegravir/emtricitabine/tenofovir alafenamide
Placebo single tablet matched to BIC/FTC/TAF taken by mouth.
Placebo single tablet matched to DOR/ISL taken by mouth.
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 was presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 48
Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one AE up to Week 48 was reported. The final analysis for this outcome is presented here.
Time frame: Up to approximately 48 weeks
Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE up to Week 48 were reported. The final analysis for this outcome is presented here.
Time frame: Up to approximately 48 weeks
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 was presented using the Data as Observed (DAO) missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
The percentage of participants with HIV-1 RNA \<40 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
The percentage of participants with HIV-1 RNA \<200 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.
Time frame: Week 144
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 48 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 48 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.
Time frame: Baseline (Day 1) and Week 48
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 96
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 96 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 96 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.
Time frame: Baseline (Day 1) and Week 96
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 144
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 144 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 144 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.
Time frame: Baseline (Day 1) and Week 144
Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 48
RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 48 was presented. The final analysis for this outcome is presented here.
Time frame: Week 48
Incidence of Viral RASs at Week 96
RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 96 was presented. The final analysis for this outcome is presented here.
Time frame: Week 96
Incidence of Viral RASs at Week 144
RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 144 was presented. The final analysis for this outcome is presented here.
Time frame: Week 144
Mean Change From Baseline in Body Weight at Week 48
Body weight was measured at baseline and at Week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 48 was presented. The final analysis for this outcome is presented here.
Time frame: Baseline (Day 1) and Week 48
Mean Change From Baseline in Body Weight at Week 96
Body weight was measured at baseline and at Week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 96 was presented. The final analysis for this outcome is presented here.
Time frame: Baseline (Day 1) and Week 96
Mean Change From Baseline in Body Weight at Week 144
Body weight was measured at baseline and at Week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 144 was presented. The final analysis for this outcome is presented here.
Time frame: Baseline (Day 1) and Week 144
Percentage of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.
Time frame: Up to approximately 47 months
Percentage of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.
Time frame: Up to approximately 38 months
Treatment-naïve participants living with Human Immunodeficiency Virus-1 (HIV-1) that had not received ≤10 days of prior antiretroviral therapy were enrolled.
| Milestone | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Started | 298 | 301 |
| Treated | 298 | 299 |
| Completed | 59 | 34 |
| Not completed | 239 | 267 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Lost to follow-up | 16 | 17 |
| Withdrew: Physician decision | 11 | 7 |
| Withdrew: Sponsor decision | 168 | 179 |
| Withdrew: Withdrawal by subject | 35 | 34 |
| Withdrew: Other | 6 | 30 |
| Milestone | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Started | 21 | 27 |
| Completed | 0 | 1 |
| Not completed | 21 | 26 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Sponsor decision | 20 | 25 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 was presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 | 88.9 | 88.3 |
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one AE up to Week 48 was reported. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48 | 90.6 | 86.3 |
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE up to Week 48 were reported. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48 | 7.4 | 3.3 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96 | 51.7 | 57.9 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 was presented using the Data as Observed (DAO) missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144 | 64.1 | 82.9 |
The percentage of participants with HIV-1 RNA \<40 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48 | 88.6 | 86.3 |
The percentage of participants with HIV-1 RNA \<200 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48 | 89.6 | 88.6 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96 | 51.0 | 57.5 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96 | 52.3 | 58.5 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144 | 64.1 | 82.9 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144 | 64.1 | 82.9 |
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 48 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 48 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.
| cells/mm^3 | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48 | 182.4 (162.0 to 202.7) | 233.5 (211.8 to 255.3) |
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 96 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 96 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.
| cells/mm^3 | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 96 | 217.05 (187.52 to 246.58) | 319.92 (290.53 to 349.32) |
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 144 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 144 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.
| cells/mm^3 | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 144 | 239.6 (177.4 to 301.8) | 350.9 (265.7 to 436.1) |
RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 48 was presented. The final analysis for this outcome is presented here.
| Participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 48 | 1 | 0 |
RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 96 was presented. The final analysis for this outcome is presented here.
| Participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Incidence of Viral RASs at Week 96 | 2 | 0 |
RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 144 was presented. The final analysis for this outcome is presented here.
| Participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Incidence of Viral RASs at Week 144 | 2 | 0 |
Body weight was measured at baseline and at Week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 48 was presented. The final analysis for this outcome is presented here.
| kilogram | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in Body Weight at Week 48 | 3.45 (2.83 to 4.06) | 3.32 (2.68 to 3.96) |
Body weight was measured at baseline and at Week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 96 was presented. The final analysis for this outcome is presented here.
| kilogram | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in Body Weight at Week 96 | 3.31 (2.45 to 4.18) | 4.13 (3.15 to 5.11) |
Body weight was measured at baseline and at Week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 144 was presented. The final analysis for this outcome is presented here.
| kilogram | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in Body Weight at Week 144 | 4.55 (2.40 to 6.70) | 3.55 (-1.46 to 8.56) |
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 96.6 | 94.0 |
An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.
| Percentage of participants | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants Who Discontinued Study Treatment Due to an AE | 14.1 | 9.0 |
Collected over Up to approximately 47 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: DOR/ISL Base Study Week 0 - Week 48 | 2/298 (0.7%) | 19/298 (6.4%) | 146/298 (49%) |
| Group 1: DOR/ISL Base Study Week 48-Week 96 | 0/266 (0%) | 14/266 (5.3%) | 115/266 (43.2%) |
| Group 1: DOR/ISL Base Study Week 96-Week 144 | 0/146 (0%) | 3/146 (2.1%) | 42/146 (28.8%) |
| Group 2: BIC/FTC/TAF Base Study Week 0 - Week 48 | 0/301 (0%) | 16/299 (5.4%) | 141/299 (47.2%) |
| Group 2: BIC/FTC/TAF Base Study Week 48 - Week 96 | 0/267 (0%) | 13/267 (4.9%) | 124/267 (46.4%) |
| Group 2: BIC/FTC/TAF Base Study Week 96 - Week 144 | 0/143 (0%) | 1/143 (0.7%) | 37/143 (25.9%) |
| Group 1: DOR/ISL Open-Label Extension Week 144-Week 168 | 0/21 (0%) | 0/21 (0%) | 3/21 (14.3%) |
| Group 2: BIC/FTC/TAF Open-Label Extension Week 144 - Week 168 | 0/27 (0%) | 0/27 (0%) | 2/27 (7.4%) |
| Group 1: DOR/ISL Post-Treatment Follow-Up | 1/112 (0.9%) | 3/112 (2.7%) | 8/112 (7.1%) |
| Group 2: BIC/FTC/TAF Post-Treatment Follow-Up | 0/128 (0%) | 1/128 (0.8%) | 2/128 (1.6%) |
| Event | Group 1: DOR/ISL Base Study Week 0 - Week 48 | Group 1: DOR/ISL Base Study Week 48-Week 96 | Group 1: DOR/ISL Base Study Week 96-Week 144 | Group 2: BIC/FTC/TAF Base Study Week 0 - Week 48 | Group 2: BIC/FTC/TAF Base Study Week 48 - Week 96 | Group 2: BIC/FTC/TAF Base Study Week 96 - Week 144 | Group 1: DOR/ISL Open-Label Extension Week 144-Week 168 | Group 2: BIC/FTC/TAF Open-Label Extension Week 144 - Week 168 | Group 1: DOR/ISL Post-Treatment Follow-Up | Group 2: BIC/FTC/TAF Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|
| Drug hypersensitivityImmune system disorders | 3/298 | 0/266 | 0/146 | 1/299 | 0/267 | 0/143 | 0/21 | 0/27 | 0/112 | 0/128 |
| Pneumonia pneumococcalInfections and infestations | 0/298 | 0/266 | 0/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 1/112 | 0/128 |
| Stab woundInjury, poisoning and procedural complications | 0/298 | 0/266 | 0/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 1/112 | 0/128 |
| DepressionPsychiatric disorders | 0/298 | 0/266 | 0/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 1/112 | 0/128 |
| Febrile convulsionNervous system disorders | 0/298 | 0/266 | 0/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 0/112 | 1/128 |
| Gestational hypertensionPregnancy, puerperium and perinatal conditions | 0/298 | 0/266 | 0/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 0/112 | 1/128 |
| Major depressionPsychiatric disorders | 0/298 | 0/266 | 0/146 | 0/299 | 0/267 | 1/143 | 0/21 | 0/27 | 0/112 | 0/128 |
| DiverticulitisInfections and infestations | 0/298 | 0/266 | 1/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 0/112 | 0/128 |
| Scrotal abscessInfections and infestations | 0/298 | 0/266 | 1/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 0/112 | 0/128 |
| Scrotal cellulitisInfections and infestations | 0/298 | 0/266 | 1/146 | 0/299 | 0/267 | 0/143 | 0/21 | 0/27 | 0/112 | 0/128 |
| Event | Group 1: DOR/ISL Base Study Week 0 - Week 48 | Group 1: DOR/ISL Base Study Week 48-Week 96 | Group 1: DOR/ISL Base Study Week 96-Week 144 | Group 2: BIC/FTC/TAF Base Study Week 0 - Week 48 | Group 2: BIC/FTC/TAF Base Study Week 48 - Week 96 | Group 2: BIC/FTC/TAF Base Study Week 96 - Week 144 | Group 1: DOR/ISL Open-Label Extension Week 144-Week 168 | Group 2: BIC/FTC/TAF Open-Label Extension Week 144 - Week 168 | Group 1: DOR/ISL Post-Treatment Follow-Up | Group 2: BIC/FTC/TAF Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 27/298 | 64/266 | 25/146 | 12/299 | 55/267 | 24/143 | 3/21 | 0/27 | 0/112 | 0/128 |
| COVID-19Infections and infestations | 42/298 | 20/266 | 2/146 | 47/299 | 29/267 | 3/143 | 0/21 | 1/27 | 0/112 | 1/128 |
| HeadacheNervous system disorders | 31/298 | 13/266 | 2/146 | 34/299 | 13/267 | 2/143 | 0/21 | 0/27 | 1/112 | 0/128 |
| CD4 lymphocytes decreasedInvestigations | 2/298 | 28/266 | 12/146 | 1/299 | 25/267 | 14/143 | 0/21 | 1/27 | 0/112 | 0/128 |
| DiarrhoeaGastrointestinal disorders | 26/298 | 6/266 | 2/146 | 20/299 | 5/267 | 2/143 | 0/21 | 0/27 | 0/112 | 1/128 |
| Weight increasedInvestigations | 19/298 | 2/266 | 0/146 | 18/299 | 8/267 | 1/143 | 0/21 | 1/27 | 1/112 | 0/128 |
| Accidental overdoseInjury, poisoning and procedural complications | 17/298 | 7/266 | 3/146 | 16/299 | 17/267 | 1/143 | 0/21 | 0/27 | 0/112 | 0/128 |
| InsomniaPsychiatric disorders | 13/298 | 4/266 | 1/146 | 19/299 | 3/267 | 1/143 | 0/21 | 0/27 | 2/112 | 0/128 |
| Upper respiratory tract infectionInfections and infestations | 15/298 | 14/266 | 4/146 | 15/299 | 11/267 | 4/143 | 0/21 | 0/27 | 7/112 | 0/128 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/298 | 11/266 | 2/146 | 14/299 | 5/267 | 0/143 | 0/21 | 0/27 | 0/112 | 0/128 |
All randomized participants.
| Age, Continuous(Years) | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF | Total |
|---|---|---|---|
| Mean | 34.7 ± 11.0 | 35.7 ± 10.9 | 35.2 ± 10.9 |
| Sex: Female, Male(Participants) | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF | Total |
|---|---|---|---|
| Female | 77 | 71 | 148 |
| Male | 221 | 230 | 451 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF | Total |
|---|---|---|---|
| Hispanic or Latino | 123 | 112 | 235 |
| Not Hispanic or Latino | 171 | 184 | 355 |
| Unknown or Not Reported | 4 | 5 | 9 |
| Race (NIH/OMB)(Participants) | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 16 | 20 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 86 | 90 | 176 |
| White | 171 | 169 | 340 |
| More than one race | 23 | 19 | 42 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Baseline Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Level(Participants) | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF | Total |
|---|---|---|---|
| ≤100,000 copies/mL | 244 | 239 | 483 |
| >100,000 copies/mL | 54 | 60 | 114 |
| Missing | 0 | 2 | 2 |
| Baseline Cluster of Differentiation 4+ (CD4+) T-Cell Count(Participants) | Group 1: DOR/ISL | Group 2: BIC/FTC/TAF | Total |
|---|---|---|---|
| <200 cells/mm^3 | 61 | 60 | 121 |
| ≥200 cells/mm^3 | 237 | 239 | 476 |
| Missing | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2020 to primary completion in Nov 2022, 32 months.
Results were first posted in Nov 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Islatravir